Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer

详细信息    查看全文

• 作者：Inti Zlobec ; Parham Minoo ; Kristi Baker ; David Haegert ; Karim Khetani ; Luigi Tornillo ; Luigi Terracciano ; Jeremy R. Jass ; Aless ; ro Lugli
• 关键词：APAF-1 ; Colorectal cancer ; Immunohistochemistry ; Tissue microarray ; Prognosis
• 刊名：European Journal of Cancer
• 出版年：2007
• 出版时间：April 2007
• 年：2007
• 卷：43
• 期：6
• 页码：1101-1107
• 全文大小：543 K

文摘

The aim of this study was to determine the prognostic value of APAF-1 in colorectal cancer (CRC). Immunohistochemistry for APAF-1 was performed on a tissue microarray of 1015 mismatch-repair (MMR) proficient and 130 sporadic MLH1-negative CRCs. The association of APAF-1 with clinico-pathological features including 10-year survival time was analysed. Methylation specific PCR was performed on a subset of MMR-proficient and MLH1-negative CRC. Loss of APAF-1 was associated with advanced T stage (p-value = 0.022), N stage (p-value = 0.009), vascular invasion (p-value = 0.001) and worse survival (p-value = 0.017) in MMR-proficient CRC. In MLH1-negative CRC, loss of APAF-1 was associated with metastasis (p-value = 0.041), worse prognosis (p-value < 0.001) and independently predicted shorter survival time (p-value < 0.001). No methylation was found in the selected region of APAF-1. APAF-1 is a marker of tumour progression in MMR-proficient CRC and an independent adverse prognostic factor in MLH1-negative CRC.